Cough - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Cough - Pipeline Review, H1 2016', provides an overview of the Cough pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cough, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cough and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Cough - The report reviews pipeline therapeutics for Cough by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Cough therapeutics and enlists all their major and minor projects - The report assesses Cough therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Cough Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Cough - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Cough pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Cough Overview 9 Therapeutics Development 10 Pipeline Products for Cough - Overview 10 Pipeline Products for Cough - Comparative Analysis 11 Cough - Therapeutics under Development by Companies 12 Cough - Therapeutics under Investigation by Universities/Institutes 13 Cough - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Unknown Stage Products 17 Cough - Products under Development by Companies 18 Cough - Products under Investigation by Universities/Institutes 19 Cough - Companies Involved in Therapeutics Development 20 Afferent Pharmaceuticals, Inc. 20 Alitair Pharmaceuticals, Inc. 21 Ario Pharma Ltd 22 AstraZeneca Plc 23 AUS Bio Limited 24 Conrig Pharma ApS 25 Daewoong Pharmaceutical Co., Ltd. 26 GlaxoSmithKline Plc 27 Glenmark Pharmaceuticals Ltd. 28 GW Pharmaceuticals Plc 29 Hyundai Pharmaceutical Co., Ltd. 30 Johnson & Johnson 31 NeRRe Therapeutics Ltd 32 Orbis Biosciences, Inc. 33 Patara Pharma, Inc. 34 Vernalis Plc 35 Cough - Therapeutics Assessment 36 Assessment by Monotherapy Products 36 Assessment by Combination Products 37 Assessment by Target 38 Assessment by Mechanism of Action 40 Assessment by Route of Administration 42 Assessment by Molecule Type 44 Drug Profiles 45 AF-219 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 benzonatate polacrilex - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 CCP-05 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 CCP-06 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 CCP-07 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 CCP-08 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 codeine + guaifenesin - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 cromolyn sodium - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 DWJ-1340 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 GRC-17536 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 GSK-2339345 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 guaifenesin + hydrocodone - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 guaifenesin ER - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 JNJ-39729209 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 lesogaberan - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 levodropropizine CR - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 MD-990 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 NEO-5024 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 NEO-5937 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 orvepitant maleate - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 S-1226 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Small Molecule to Antagonize TRPA-1 for Pain And Respiratory Disorders - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 Small Molecules to Agonize CB1 and CB2 for Chronic Cough and Inflammatory Skin Diseases - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 ST-015 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 XEND-0501 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 Cough - Recent Pipeline Updates 74 Cough - Dormant Projects 80 Cough - Discontinued Products 83 Cough - Product Development Milestones 84 Featured News & Press Releases 84 Dec 21, 2015: Vernalis Announces Successful Completion of CCP-07 Pivotal Single-Dose Comparative Bioavailability Study 84 Oct 12, 2015: Vernalis announces start of CCP-08 12 month stability testing 84 Sep 28, 2015: Afferent Pharmaceuticals Announces Positive Results in Phase 2b Chronic Cough Trial 84 Jul 01, 2015: Spriaso Announces Approval of New Drug Application for the Long Acting Codeine Antitussive With a Popular Anti-Histamine 85 Jun 11, 2015: Vernalis announces CCP-07 starts 12 month stability testing 86 Nov 25, 2014: Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published In The Lancet 86 Jul 22, 2014: Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 87 Apr 29, 2014: Second Product in Vernalis' Cough Cold Pipeline Achieves Proof-of-Concept 88 Dec 11, 2013: Ario Pharma to Develop Novel Therapeutics for Respiratory Indications 88 Sep 09, 2013: Afferent Pharmaceuticals Reports Positive Phase 2 Clinical Data for the Company's Lead P2X3 Antagonist, AF-219 89 Appendix 91 Methodology 91 Coverage 91 Secondary Research 91 Primary Research 91 Expert Panel Validation 91 Contact Us 91 Disclaimer 92
List of Tables
Number of Products under Development for Cough, H1 2016 10 Number of Products under Development for Cough - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Number of Products under Investigation by Universities/Institutes, H1 2016 13 Comparative Analysis by Late Stage Development, H1 2016 14 Comparative Analysis by Clinical Stage Development, H1 2016 15 Comparative Analysis by Early Stage Development, H1 2016 16 Comparative Analysis by Unknown Stage Development, H1 2016 17 Products under Development by Companies, H1 2016 18 Products under Investigation by Universities/Institutes, H1 2016 19 Cough - Pipeline by Afferent Pharmaceuticals, Inc., H1 2016 20 Cough - Pipeline by Alitair Pharmaceuticals, Inc., H1 2016 21 Cough - Pipeline by Ario Pharma Ltd, H1 2016 22 Cough - Pipeline by AstraZeneca Plc, H1 2016 23 Cough - Pipeline by AUS Bio Limited, H1 2016 24 Cough - Pipeline by Conrig Pharma ApS, H1 2016 25 Cough - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016 26 Cough - Pipeline by GlaxoSmithKline Plc, H1 2016 27 Cough - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2016 28 Cough - Pipeline by GW Pharmaceuticals Plc, H1 2016 29 Cough - Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2016 30 Cough - Pipeline by Johnson & Johnson, H1 2016 31 Cough - Pipeline by NeRRe Therapeutics Ltd, H1 2016 32 Cough - Pipeline by Orbis Biosciences, Inc., H1 2016 33 Cough - Pipeline by Patara Pharma, Inc., H1 2016 34 Cough - Pipeline by Vernalis Plc, H1 2016 35 Assessment by Monotherapy Products, H1 2016 36 Assessment by Combination Products, H1 2016 37 Number of Products by Stage and Target, H1 2016 39 Number of Products by Stage and Mechanism of Action, H1 2016 41 Number of Products by Stage and Route of Administration, H1 2016 43 Number of Products by Stage and Molecule Type, H1 2016 44 Cough Therapeutics - Recent Pipeline Updates, H1 2016 74 Cough - Dormant Projects, H1 2016 80 Cough - Dormant Projects (Contd..1), H1 2016 81 Cough - Dormant Projects (Contd..2), H1 2016 82 Cough - Discontinued Products, H1 2016 83
Global amino acids market size is anticipated to be valued at USD 35.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in animal feed additive demand owing to regulate metabolism in livestock production owing to growiRead More...
Global Aerial Work Platform (AWP) truck market is expected to be valued at USD 8,003.7 million by 2022, as per a new research report by Radiant Insights, Inc. Rapid infrastructure growth due to rising real estate investment is expected to drive the iRead More...
Global fumaric acid market size is anticipated to be valued at USD 764.8 million by 2020, as per a new research report by Radiant Insights, Inc. Growing processed food demand coupled with RTD (ready-to-drink) beverages consumption is expected to drivRead More...
Global advanced energy storage systems market size is anticipated to be valued at USD 24.8 billion by 2022, as per a new research report by Radiant Insights, Inc. Increasing energy consumption coupled with strong energy demand for industrial, commercRead More...
Global geotextile market size is likely to be valued at USD 8.24 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing use in soil reinforcement activity coupled with growing application scope in road & railway developmenRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.